The United States will spend 3.2 billion US dollars to develop antiviral drugs | International war "epidemic" operation

According to the US Consumer News and Business Channel website, the US Biden administration recently announced that it will invest US$3.2 billion to advance the research and development of antiviral drugs to treat the new coronavirus and other viruses that may cause epidemics.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical adviser to the White House, said at a press conference held last Thursday that this new plan is called the "antiviral pandemic plan." It will accelerate the progress of clinical trials of candidate drugs and develop next-generation treatment methods.

Another statement from the US government stated that as part of the plan, the National Institutes of Health (NIH) will "evaluate, prioritize, and advance" antiviral drug candidates into the second phase of clinical trials, and "guide drug candidates to accelerate progress." ".

Fauci pointed out that although vaccines are still the "core weapon" of the United States against the new crown pneumonia epidemic, antiviral drugs are an important supplement to existing vaccines. Other officials also said that although the vaccine is very effective in reducing the infection rate of the American people, for those who are indeed infected with the virus and those whose immune system does not respond well to the vaccine, more other therapies are still needed.

It is reported that of the 3.2 billion US dollars, more than 300 million US dollars are used to provide support for research and laboratories; about 1 billion US dollars are used for preclinical and clinical evaluation of related therapies, and nearly 700 million US dollars are used to pass NIAID and advanced biomedical research. Develop and manufacture related therapies and drugs with the Development Bureau. In addition, the plan will allocate 1.2 billion US dollars to support the establishment of drug discovery teams for the new crown virus and other potential viruses.

At present, some therapies for new coronary pneumonia are in the development process and are expected to be launched in the United States by the end of this year. For example, Pfizer started an early clinical trial in March this year to test an experimental oral drug that can be used to treat the onset of new coronary pneumonia. This drug belongs to the family of protease inhibitors and works by inhibiting an enzyme required for virus replication in human cells. Protease inhibitors have been used to treat other viral diseases, such as AIDS and hepatitis C.

NIH Director Francis Collins added: "We will use existing technology to build a platform for the discovery and development of effective antiviral drugs, help overcome the new crown epidemic, and prepare for other viruses that may cause epidemics in the future. ready."

Source: Science and Technology Daily

Post a Comment

Previous Post Next Post